A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) US/Canadian population who had progressed on crizotinib (NP28761) Meeting Abstract
| Authors: | Gandhi, L.; Shaw, A.; Gadgeel, S. M.; Riely, G.; Cetnar, J.; West, H. J.; Camidge, D. R.; Socinski, M. A.; Chiappori, A.; Mekhail, T.; Chao, B. H.; Borghaei, H.; Gold, K. A.; Zeaiter, A. H.; Bordogna, W.; Balas, B.; Puig, O.; Henschel, V.; Ou, S. H. I. |
| Abstract Title: | A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) US/Canadian population who had progressed on crizotinib (NP28761) |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036901732 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2015.33.15_suppl.8019 |
| Notes: | Meeting Abstract: 8019 -- Source: Wos |
